Skip to content

EU · EudraLex Vol.4

EU GMP Annex 1 2.6

2. Principle

Section text

The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be assessed for any impact on the CCS before and after implementation.

Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.